Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

Bibliography

• Calverley PM, Rabe KF, Goehring UM, Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
   PubMed Web of Science ®Google Scholar
• Hermann R, Lahu G, Hauns B, “Total PDE4 inhibitory activity”: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions. Eur Respir J 2006;28:436s
   Google Scholar
• Lahu G, Hunnemeyer A, von Richter O, Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol 2008;48:1339-49
   PubMed Web of Science ®Google Scholar
• von Richter O, Lahu G, Huennemeyer A, Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet 2007;46:613-22
   PubMed Web of Science ®Google Scholar
• David M, Zech K, Seiberling M, Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high oral bioavailability. J Allergy Clin Immunol 2004;113:S220-1
   Google Scholar
• Bethke TD, Boehmer GM, Hermann R, Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007;47:26-36
   PubMed Web of Science ®Google Scholar
• Hermann R, Nassr N, Lahu G, Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. Clin Pharmacokinet 2007;46:403-16
   PubMed Web of Science ®Google Scholar
• Lahu G, Huennemeyer A, Herzog R, Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 2009;47:236-45
   PubMed Web of Science ®Google Scholar
• Lahu G, Nassr N, Herzog R, Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-Oxide. J Clin Pharmacol 2010; [Epub ahead of print]
   Web of Science ®Google Scholar
• Nassr N, Huennemeyer A, Herzog R, Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. Br J Clin Pharmacol 2009;68:580-7
   PubMed Web of Science ®Google Scholar
• The E14 Implementation Working Group. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH Guidelines E14; 2005
   Google Scholar
• Bundschuh DS, Eltze M, Barsig J, In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233-47
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005;18:93-101
   PubMed Web of Science ®Google Scholar
• Schmidt BM, Kusma M, Feuring M, The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001;108:530-6
   PubMed Web of Science ®Google Scholar
• Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94
   PubMed Web of Science ®Google Scholar
• Okumura S, Suzuki S, Ishikawa Y. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene. J Pharmacol Sci 2009;109:354-9
   PubMedGoogle Scholar
• Singh K, Xiao L, Remondino A, Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 2001;189:257-65
   PubMed Web of Science ®Google Scholar
• Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-78
   PubMed Web of Science ®Google Scholar
• Ding B, Abe J, Wei H, Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005;111:2469-76
   PubMed Web of Science ®Google Scholar
• Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007;100:489-501
   PubMed Web of Science ®Google Scholar
• Geelen P, Drolet B, Rail J, Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-7
   PubMed Web of Science ®Google Scholar
• Morganroth J, Ilson BE, Shaddinger BC, Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004;93:1378-83, A6
   PubMed Web of Science ®Google Scholar
• Roflumilast: assessment of nonclinical cardiovascular safety. Data on file, Nycomed GmbH (previously Altana Pharma AG) 177/2003; 2003
   Google Scholar
• Data on file, Nycomed GmbH (previously Altana Pharma AG) 37/2000; 2000
   Google Scholar
• Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009;32:359-78
   PubMed Web of Science ®Google Scholar
• Malik M, Hnatkova K, Schmidt A, Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009;49:674-83
   PubMed Web of Science ®Google Scholar
• Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001;24:323-51
   PubMed Web of Science ®Google Scholar
• Rabe KF, Bateman ED, O'Donnell D, Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
   PubMed Web of Science ®Google Scholar
• Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
   PubMed Web of Science ®Google Scholar